Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
19 patents granted to the 6 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Soligenix, Inc.’s names, not what it holds today.
Patents granted
19
19 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 1 in 2023
Applications published
23
2 of them in 2025
Names they are printed under
6
its own name, a former name, a subsidiary
By yearGrantedApplications published
'08'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name6 counted
Soligenix, Inc. its own name
named as the applicant on its applications, in US
20 publishedSoligenix, Inc. its own name
US, as the owner printed on each patent
0 publishedDOR Biopharma, Inc. a former name
US, as the owner printed on each patent
2 publishedImmunoTherapeutics, Inc. a former name
US, as the owner printed on each patent
0 publishedEndorex Corporation a former name
US, as the owner printed on each patent
0 publishedEnteron Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 24, 2024 | 12,097,291 | Thermostable vaccine compositions and methods of preparing same | Pharmaceuticals | Soligenix, Inc. |
| Oct 3, 2023 | 11,771,757 | Compositions and methods of manufacturing trivalent filovirus vaccines | Pharmaceuticals | Soligenix, Inc. |
| Sep 6, 2022 | 11,433,129 | Compositions and methods of manufacturing trivalent filovirus vaccines | Pharmaceuticals | Soligenix, Inc. |
| Apr 26, 2022 | 11,311,598 | Peptides and analogs for use in the treatment of oral mucositis | Pharmaceuticals | Soligenix, Inc. |
| Jan 7, 2020 | 10,526,268 | Systems and methods for producing synthetic hypericin | Organic fine chemistry | Soligenix, Inc. |
| May 21, 2019 | 10,293,041 | Multivalent stable vaccine composition and methods of making same | Pharmaceuticals | Soligenix, Inc. |
| Apr 9, 2019 | 10,253,068 | Peptides and analogs for use in the treatment of oral mucositis | Pharmaceuticals | Soligenix, Inc. |
| Aug 21, 2018 | 10,053,413 | Systems and methods for producing synthetic hypericin | Organic fine chemistry | Soligenix, Inc. |
| Dec 26, 2017 | 9,850,279 | Peptides and analogs for use in the treatment of oral mucositis | Pharmaceuticals | Soligenix, Inc. |
| Sep 19, 2017 | 9,763,963 | Topically active steroids for use in interstitial pulmonary fibrosis | Pharmaceuticals | Soligenix, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jun 19, 2025 | 2025/0195604 | Compositions and Methods of Treatment of Certain Vasculitis Syndromes | Pharmaceuticals | Soligenix, Inc. |
| Apr 24, 2025 | 2025/0127761 | Telmisartan Nanosuspension for Therapy of Respiratory Infections and Methods of Making and Using Same | Pharmaceuticals | Soligenix, Inc. |
| Jun 13, 2024 | 2024/0189413 | Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines | Pharmaceuticals | Soligenix, Inc. |
| Jan 11, 2024 | 2024/0009297 | Antibody/Adjuvant Compositions and Methods of Immune Response Generation against Coronaviruses | Pharmaceuticals | Soligenix, Inc. |
| Mar 23, 2023 | 2023/0093418 | Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines | Pharmaceuticals | Soligenix, Inc. · patent 11,771,757 granted from it |
| Jan 26, 2023 | 2023/0024050 | Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell Lymphoma | Medical technology | Soligenix, Inc. |
| Nov 25, 2021 | 2021/0361579 | Thermostable Vaccine Compositions and Methods of Preparing same | Pharmaceuticals | Soligenix, Inc. · patent 12,097,291 granted from it |
| Dec 3, 2020 | 2020/0376109 | Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines | Pharmaceuticals | Soligenix, Inc. · patent 11,433,129 granted from it |
| Oct 15, 2020 | 2020/0323946 | Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis | Pharmaceuticals | Soligenix, Inc. · patent 11,311,598 granted from it |
| May 21, 2020 | 2020/0155571 | Topically Active Steroids for Use in Radiation and Chemotherapeutics Injury | Pharmaceuticals | Soligenix, Inc. |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.